Table 1 Baseline demographics of treatment-naïve RA patients recruited into the Pathobiology of Early Arthritis Cohort (PEAC)
|  | Lympho-myeloid (N = 49) | Diffuse myeloid (N = 18) | Pauci immune fibroid (N = 16) | Total (N = 83) | p-value |
|---|---|---|---|---|---|
Age (years) | 52.3 (16.2) | 50.4 (16.5) | 53.2 (15.0) | 52.1 (15.9) | 0.865 |
Gender | Â | Â | Â | Â | 0.608 |
 F | 37 (75.5%) | 12 (66.7%) | 13 (81.2%) | 62 (74.7%) |  |
 M | 12 (24.5%) | 6 (33.3%) | 3 (18.8%) | 21 (25.3%) |  |
Disease duration (months) | 5.9 (3.3) | 4.8 (2.6) | 7.0 (3.5) | 5.8 (3.3) | 0.152 |
RF | Â | Â | Â | Â | 0.203 |
 pos | 32 (69.6%) | 9 (52.9%) | 7 (46.7%) | 48 (61.5%) |  |
 neg | 14 (30.4%) | 8 (47.1%) | 8 (53.3%) | 30 (38.5%) |  |
CCP | Â | Â | Â | Â | 0.025 |
 pos | 39 (84.8%) | 10 (55.6%) | 9 (60.0%) | 58 (73.4%) |  |
 neg | 7 (15.2%) | 8 (44.4%) | 6 (40.0%) | 21 (26.6%) |  |
DAS28 | 6.2 (1.2) | 5.6 (1.2) | 5.2 (1.6) | 5.8 (1.3) | 0.029 |
ESR (mm/hr) | 50.9 (28.1) | 37.6 (25.4) | 30.8 (27.7) | 44.1 (28.4) | 0.025 |
CRP (μg/mL) | 25.0 (26.5) | 17.5 (26.0) | 14.4 (41.7) | 21.3 (29.9) | 0.395 |
TJC | 12.6 (7.2) | 9.9 (6.3) | 10.9 (8.9) | 11.7 (7.4) | 0.396 |
SJC | 8.4 (5.7) | 7.1 (4.3) | 5.2 (5.0) | 7.5 (5.4) | 0.116 |
VAS | 67.9 (24.0) | 61.1 (21.7) | 57.8 (27.1) | 64.5 (24.2) | 0.287 |
HAQ | 1.6 (0.8) | 1.4 (0.6) | 1.6 (0.8) | 1.5 (0.7) | 0.499 |
DAS28 EULAR | Â | Â | Â | Â | 0.603 |
 Good | 15 (36.6%) | 4 (30.8%) | 7 (53.8%) | 26 (38.8%) |  |
 Moderate | 20 (48.8%) | 8 (61.5%) | 4 (30.8%) | 32 (47.8%) |  |
 None | 6 (14.6%) | 1 (7.7%) | 2 (15.4%) | 9 (13.4%) |  |